MedPage Today on MSN1d
Studies Hint at Potential Negative Effects of GLP-1 Drugs in Orthopedic Patients
SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...
pharmaphorum2d
AstraZeneca improves diabetes pen to maintain its market share
The EC made its decision based on data from DURATION-NEO-1 clinical trial comparing Bydureon BCise and AZ'[s twice-daily exenatide formulation, Byetta. After 28 weeks of treatment, patients ...
pharmaphorum1d
BMS completes acquisition of Amylin, AZ buys equal share
The portfolio includes Byetta, launched in 2005, and the longer-acting version, Bydureon, which was approved by US regulators earlier this year. Upon the exercise of this option, AZ will pay BMS a ...
Diabetes.co.uk3d
Retatrutide: How it Works, Evidence, Side Effects
Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...
CNET on MSN1d
GLP-1 Meds Like Ozempic: Know Potential Benefits, Risk Factors and Overdose Info
G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...